A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY.
Jwa Hoon KimChanghoon YooSeyoung SeoJae Ho JeongBaek-Yeol RyooKyu-Pyo KimJung Bok LeeKeun-Wook LeeJi-Won KimIl-Hwan KimMyoungjoo KangHae Won RyuJaekyung CheonSook Ryun ParkPublished in: Cancers (2022)
DOAC therapy further increased the risk of bleeding compared with dalteparin in patients with active advanced upper GI tract, hepatobiliary, or pancreatic cancer, suggesting that extra caution should be taken when selecting anticoagulants for CA-VTE.